CILOXAN 3 mg/ml ear drops, solution

  • Name:

    CILOXAN 3 mg/ml ear drops, solution

  • Company:
    info
  • Active Ingredients:

    Ciprofloxacin hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 25/11/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 8/4/2019

Click on this link to Download PDF directly

Novartis Ireland Limited

Novartis Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Aclasta 5 mg solution for infusion Active Ingredients Zoledronic acid monohydrate
Medicine Name Afinitor Tablets Active Ingredients Everolimus
Medicine Name Aimovig Active Ingredients Erenumab
Medicine Name Atriance 5 mg/ml solution for infusion Active Ingredients Nelarabine
Medicine Name Azarga 10mg/ml + 5mg/ml eye drops, suspension Active Ingredients Brinzolamide, Timolol Maleate
Medicine Name Azopt 10mg/ml eye drops suspension Active Ingredients Brinzolamide
Medicine Name Cataflam 50 mg Coated Tablets Active Ingredients Diclofenac Potassium
Medicine Name Certican Tablets Active Ingredients Everolimus
Medicine Name CILOXAN 3 mg/ml ear drops, solution Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Co-Diovan 160 mg/12.5 mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 160mg/25mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 320mg/12.5mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 320mg/25mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 80mg/12.5mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Cosentyx 150 mg solution for injection in pre-filled pen Active Ingredients secukinumab
Medicine Name Desferal 500mg Vials Active Ingredients Desferrioxamine Mesylate
Medicine Name Diovan 160 mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 320mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 3mg/ml Oral Solution Active Ingredients Valsartan
Medicine Name Diovan 40 mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 80 mg film-coated tablets Active Ingredients Valsartan
Medicine Name DuoTrav Eye Drops Solution Active Ingredients Timolol Maleate, Travoprost
Medicine Name Entresto 24mg/26mg, 49mg/51mg and 97mg/103mg film-coated tablets Active Ingredients Sacubitril, Valsartan
Medicine Name Estradot Transdermal Patches Active Ingredients Estradiol Hemihydrate
Medicine Name Eucreas 50mg / 850mg and 50mg / 1000mg film-coated tablets Active Ingredients Metformin Hydrochloride, Vildagliptin
1 - 0 of 116 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 25 November 2019 PIL

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 8 April 2019 SmPC

Reasons for updating

  • File format updated to PDF

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 12 November 2018 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 16 July 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

MAT Transfer

Updated on 30 May 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 30 May 2017 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

- Sections 7,8 and 10 updated following change of ownership from Alcon to Novartis.

Updated on 26 May 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 26 May 2017 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - date of revision

Updated on 11 February 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

- Update of ADR reporting and IMB to HPRA name change

Updated on 9 February 2015 PIL

Reasons for updating

  • Change to side-effects

Updated on 25 September 2014 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 25 March 2014 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 18 February 2014 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Spc updated to alingn with CCSI changes.

Updated on 12 February 2014 PIL

Reasons for updating

  • Change to instructions about missed dose
  • Change to instructions about overdose
  • Change to side-effects

Updated on 10 September 2013 SmPC

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 6.4
The storage conditions for Ciloxan 0.3% ear drops, solution cahnged from ‘no labelled storage conditions’ to ‘Do not refrigerate or freeze.

Updated on 5 September 2013 PIL

Reasons for updating

  • Change to storage instructions
  • Change to date of revision

Updated on 15 May 2013 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update of MAH address and Date of revision of text

Updated on 13 May 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 7 December 2012 SmPC

Reasons for updating

  • Change to section 4 - Clinical particulars
  • Change to section 5 - Pharmacological properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes affected Sec 4 and 5 of the SPC to be in line with the Company Core Safety Profile.

Updated on 5 December 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects

Updated on 7 December 2011 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 24 February 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In Section 2, Qualitative and quantitative composition, the statements - ‘3.0 mg/ml ciprofloxacin equivalent to 3.5 mg/ml ciprofloxacin hydrochloride. For excipients, see 6.1.’ - are replaced with ‘Each ml contains 3mg ciprofloxacin as ciprofloxacin hydrochloride. Excipients: contains benzalkonium chloride 0.06mg/ml. For a full list of excipients, see section 6.1.’

 

In Section 4.3, Contraindications, ‘Hypersensitivity to the active substance or to any of the excipients. Hypersensitivity to quinolones.’ is replaced with ‘Hypersensitivity to ciprofloxacin, to other quinolones or any of the excipients.’

 

In section 4.4, Special warnings and precautions for use, the statement ‘Efficacy and safety in children less than one year old have not been assessed.’ is removed. A statement regarding ‘Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures-’ is added.

 

In Section 6.3, Shelf-life, ‘4 weeks after first opening.’ is replaced with ‘Discard 4 weeks after first opening.’

 

In Section 6.4, Special precautions for storage, ‘No special precautions for storage.’ is replaced with ‘This medicinal product does not require any special storage precautions.’

 

In Section 9, Date of first authorisation or renewal of the authorisation, ‘Date of last renewal: 03 February 2011’ is added.

 

In Section 10, Date of revision of the text, the date of revision is updated to February 2011.

Updated on 12 August 2010 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 18 May 2010 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.1 - 'Consideration should be given to official guidance on the appropriate use of antibacterial agents' added

Section 4.2 - Heading 'Adults and children 1 year and above' added

Section 4.3 - 'Hypersensitivty to the active substance or to any of the excipients' and 'Hypersensitivty to quinolones'.

Section 10 - Changed to 'February 2010'

Updated on 14 September 2009 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided